GCCL(Global Clinical Central Lab), a leading Korean clinical trial sample analysis company, reinforced its position in the ...

Bernard emphasized strong performances in the QIAstat Diagnostics and QuantiFERON portfolios, with QIAstat achieving 25% CER growth in Q4 and over 660 new system placements in 2024. QuantiFERON grew ...

Almost three-quarters, 73%, of global institutional investors expect private markets investments to beat public markets soon.